Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Doctors ran countless tests but found nothing conclusive
Sigma-Tau Pharmaceuticals Inc, Gaithersburg, MD
This multi-receptor mechanism distinguishes it from existing agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 agonist), and has been associated with pronounced reductions in body weight and improvements in metabolic parameters in early clinical studies
Estimation of -cell mass by metabolic tests: necessary, but how sufficient
Patients should be informed that whilst the mechanism suggests potential cardiovascular benefits, definitive outcome data are awaited
US$ 23.88
US$ 24.35
US$ 24.59
US$ 25.13
US$ 28.57
